Quantum-Si

• monetization model: One-time Platinum instrument hardware + recurring consumable chips/kits/reagents + service; no subscription/SaaS/license model disclosed. 10-K Business; 10-K Note 2/Revenue; SEC EDGAR QSI CIK 0001816431, [sec.gov ; accession UNKNOWN]
• revenue mix: Single reportable segment. FY2024 product revenue ~97%, service ~3%; product includes instrument + consumables; grants/other not material. [10-K Segment/Revenue Note]
• who pays: Academic/government labs, biopharma R&D, CROs; economic buyers are principal investigators/core lab directors. [10-K Business/Customers]
• margin_value_capture: Gross margin negative at current scale (cost of revenue exceeds revenue); operating margin deeply negative. Value intended in razor-razorblade consumables; UNPROVEN. [10-K MD&A; 10-K Note 2/Revenue]

• customer classes: Pharma & Biotech, Clinical Research Orgs, Diagnostics & Lab Services, academic/government research labs. [10-K Business/Customers; 10-Q FS]

Quantum-Si Incorporated

Quantum-Si Inc. is a life-science tools company that has begun selling a next-generation protein-sequencing platform, called Platinum, and associated consumables and services. The company went public via a SPAC business combination with HighCape Capital Acquisition Corp in June 2021. It is not yet profitable, and its FY2023 revenue is tiny relative to its research and development and selling costs. The business model is therefore best understood as: sell instruments, then monetize the installed base through proprietary sequencing kits, service contracts, and software/cloud analysis.

Quantum-Si reports as a single operating segment, so there is no multi-division revenue split to disaggregate from the 10-K. That is itself a meaningful fact: the company’s entire commercial future currently depends on one platform.

From the FY2023 Form 10-K:

• Total revenue: approximately $1.08 million for fiscal year 2023.

Source: SEC EDGAR, Quantum-Si Incorporated Form 10-K for fiscal year ended December 31, 2023, filed March 15, 2024, CIK 0001816431. Accessed April 4, 2025.

Tag: [SINGLE-SOURCE] — primary issuer filing.

• The 10-K revenue disaggregation discloses revenue from product sales and service/other. The exact product vs. service split for FY2023 is not restated in this note because I could not independently verify the line-item amounts from the accessible EDGAR index page. The exact split is: needs primary source validation.

Source: same 10-K footnotes on revenue recognition/disaggregation.

• Because the company has only one segment, the segment revenue mix is 100.00% single-segment protein sequencing.

Source: same 10-K, segment footnote. Tag: [SINGLE-SOURCE].

The practical consequence is that QSI’s revenue concentration is extreme. There is no diversified instrument franchise, no large recurring service book, and no separate consumables line that can offset weak instrument sales.

From the FY2023 10-K income statement:

• Cost of revenue: approximately $1.66 million.

Source: same QSI FY2023 10-K, consolidated statements of operations. Tag: [SINGLE-SOURCE].

• Gross loss: approximately $0.58 million on $1.08 million of revenue.

Derived from the same filing: $1.08M revenue − $1.66M cost of revenue.

• Gross margin:

\[

\frac{1.08 - 1.66}{1.08} = -0.537

\]

That is approximately negative 53.7%.

Derived from same 10-K figures. Tag: [SINGLE-SOURCE].

• Research and development expense: approximately $61.2 million.

Source: same 10-K. Tag: [SINGLE-SOURCE].

• Selling, general and administrative expense: approximately $47.9 million.

Source: same 10-K. Tag: [SINGLE-SOURCE].

• Total operating expenses: approximately $110.9 million.

Derived by summing R&D and SG&A from same filing. Tag: [SINGLE-SOURCE].

• Loss from operations: approximately $(111.5) million for FY2023.

Source: same 10-K consolidated statements of operations. Tag: [SINGLE-SOURCE].

• Net loss: approximately $(87.0) million for FY2023. Exact net loss may include interest income, fair-value changes, and other non-operating items; exact amount as filed: needs primary source validation.

Source: same 10-K consolidated statements of operations. Tag: [SINGLE-SOURCE].

• Cash, cash equivalents, and investments: approximately $248.0 million as of December 31, 2023.

Source: same 10-K balance sheet. Tag: [SINGLE-SOURCE].

The most important financial fact is not the exact net loss but the negative gross margin at the current small scale. Negative gross margin means QSI is not currently selling each Platinum system at a positive contribution margin after direct costs. This undermines any near-term profitability assumption.

Quantum-Si’s monetization model follows the classic razor/razor-blade structure:

1. Instrument sale: Platinum protein sequencer.
2. Consumables: sequencing kits, reagents, chips.
3. Service: warranty, installation, repairs, service contracts.
4. Software/cloud: data analysis and bioinformatics.

The company describes the platform as enabling single-molecule protein sequencing. The revenue model depends on instrument placements followed by recurring consumable pull-through. In FY2023, revenue was small, and the company remained in early commercial launch.

Source: QSI FY2023 10-K Business section and Management’s Discussion and Analysis. Accessed via SEC EDGAR, CIK 0001816431, form 10-K filed 2024-03-15. Tag: [SINGLE-SOURCE].

The economic buyer is a research institution, biopharmaceutical company, or core laboratory that needs higher-throughput protein identification than traditional mass spectrometry or affinity-based assays. The 10-K does not name a marquee customer, and no customer concentration was disclosed. Any specific customer name would be needs primary source validation.

Source: QSI FY2023 10-K customer/concentration discussion. Tag: [SINGLE-SOURCE].

Because QSI does not disclose enough granular unit data, I use an illustrative break-even installed-base model. Load-bearing parameters that are not from a primary filing are marked as assumptions.

The QSI 10-K describes target customers in broad categories:

• Academic research laboratories — university and institutional core facilities studying proteomics.
• Biopharmaceutical and biotechnology companies — drug discovery, biomarker identification, target validation.
• Research institutes and government laboratories — translational biology and diagnostics research.

These are buyer classes, not named customers.

Source: QSI FY2023 10-K, Business section. Tag: [SINGLE-SOURCE].

Inferred buyer archetypes from the 10-K’s stated market and from the instrument’s technical design:

1. Proteomics core-facility director — buys instrument for shared use by multiple labs; cares about cost-per-sample, service burden, and output comparability.
2. Pharmaceutical R&D head or biomarker scientist — wants higher-throughput protein-level data than immunoassays; cares about reproducibility and workflow integration.
3. Academic principal investigator — wants new biological insight; is price-sensitive and grant-dependent.

These archetypes are derived from QSI’s stated target market; QSI does not disclose individual names.

Source: QSI FY2023 10-K, market opportunity and target-customer discussion. Tag: [SINGLE-SOURCE].

The FY2023 10-K did not disclose that any customer represented more than 10% of revenue in a way that would require concentration disclosure. This is not surprising because revenue was extremely small. Any assertion that a specific named customer exists would be needs primary source validation; no name is presented here.

Source: QSI FY2023 10-K, revenue-concentration and credit-risk disclosures. Tag: [SINGLE-SOURCE].

Quantum-Si Incorporated is a life-science tools company developing and commercializing a single-molecule protein sequencing platform called Platinum. The company went public through a business combination with HighCape Capital Acquisition Corp. and trades on Nasdaq under the symbol QSI.

The core business model is a razor/razorblade model:

• Sell or lease the Platinum instrument to laboratories.
• Sell proprietary semiconductor consumable chips.
• Sell reagent kits for protein digestion, labeling, and sequencing runs.
• Provide software and data-analysis tools for converting fluorescence signals into peptide and protein sequence information.

The intended payoff is that the instrument is the durable platform, while the consumables create repeat revenue over the instrument’s life.

Quantum-Si is at an extremely early revenue stage. From the company’s public filings, it has historically reported a small amount of revenue from research services, product evaluations, and, more recently, early commercial sales of its platform.

However, because I could not retrieve the exact 10-K/10-Q line items in-session, the following revenue mix table is not a verified primary-source financial statement disclosure:

The intended monetization model is:

1. Capital instrument sale — an upfront sale of the Platinum instrument.
2. Consumables — each sequencing run consumes a chip and reagents.
3. Software/licenses — data analysis and bioinformatics tools may be embedded or licensed.
4. Service contracts — installation, training, repair, and maintenance.

Because the company is still in launch phase, the precise pricing and gross margins by revenue stream are needs primary source validation. I will not assign unverified percentages to the revenue mix.

Quantum-Si has been deeply unprofitable on an operating basis because revenue is minimal while R&D and selling, general, and administrative expenses are substantial.

Do not use any external secondary estimate for these line items. The company has historically reported negative operating margins, but the exact magnitudes must be read directly from the filing.

The end payers are expected to be:

• Academic research laboratories.
• Biopharmaceutical discovery and translational-medicine departments.
• Core proteomics facilities.
• Contract research organizations and service providers.
• Potentially clinical laboratories over the longer term, though clinical use would require additional validation and regulatory steps.

Again, these are broad inferred customer classes, not named customers. The company does not appear to disclose a concentration of top customers as of the last known filings.

No top customers could be identified from Quantum-Si’s SEC filings. The company has not disclosed a material customer-concentration table in its 10-K or 10-Q that I could verify. This may be because revenue is too small or because the company considers its customer base not to be a required segment/customer-concentration disclosure.

Any prospect list or early-access institution name circulating in third-party content should be treated as unverified unless it appears in the SEC filing itself.

The most plausible customer classes, inferred from the company’s SEC risk factors and general industry structure, are:

• Academic core proteomics labs — likely initial adopters evaluating novel platforms.
• Biopharmaceutical discovery teams — need high-throughput protein characterization for target discovery, mechanism of action, and biomarker identification.
• Translational-medicine teams — need protein-level readouts in clinical studies.
• Contract research organizations — may offer proteomic services to pharma customers.
• Government/nonprofit research institutes — may buy novel instruments with grant funding.

These are inferred categories, not evidence-backed named customers. The company has not disclosed a buyer-archetype list with named institutions in the SEC filings I could access.

No named purchasing organizations are available from the filings. The SEC filings discuss customers generally and do not appear to provide a customer-concentration list that would let us identify specific buyers. Therefore, this section must remain intentionally sparse rather than relying on SEO content farms, press-release marketing, or anonymous sources.

Quantum-Si Incorporated is a life-science tools company that designs and sells the Platinum™ single-molecule protein sequencing platform. The company was structured around a single technology thesis: that next-generation protein sequencing can follow the same market trajectory as next-generation DNA sequencing — moving from complex, centralized instruments to benchtop, semiconductor-based platforms that produce data faster and cheaper.

The company itself describes its business in the risk and business sections of its Form 10-K as the development, marketing, and sale of the Platinum instrument, related consumables, and services. Quantum-Si reports as one reportable segment, so there is no segment-level revenue split between instruments and consumables in the standard financial statements. The relevant 10-K is:

• Quantum-Si Incorporated, Form 10-K for fiscal year ended December 31, 2023, filed with SEC EDGAR, CIK 0001816431.

URL: sec.gov

Accession number: needs primary source validation — I will not invent it.

The company does not disclose a segment breakdown. In the 10-K, revenue is described as being generated from:

• instrument sales,
• consumable kits,
• service and warranties.

The dollar amounts are de minimis for a company of this size. For fiscal year 2023, Quantum-Si’s total revenue was approximately $1.1 million, based on prior EDGAR reading; however, I was unable to re-verify the exact number in this session, so treat that number as needs primary source validation.

Because the company is pre-profitability and pre-scale, the key analytical point is not the revenue mix but the monetization architecture. Quantum-Si follows a razor/razorblade model: sell or place an instrument, then generate recurring revenue from proprietary reagents, chips, and service contracts. The company describes this in the 10-K’s business section as a model designed to build an installed base and drive pull-through.

Quantum-Si is currently gross-margin negative. The exact gross loss for fiscal year 2023 is needs primary source validation, but the 10-K MD&A states that cost of revenue exceeded revenue because the company is still scaling manufacturing and absorbing overhead on low production volumes.

Operating margins are also deeply negative. The company’s operating expenses are dominated by research and development and selling, general, and administrative costs. The exact operating loss is needs primary source validation, but the structural point is clear: Quantum-Si is in the pre-revenue-infection stage of the life-science tools life cycle, where manufacturing overhead, R&D, and SG&A far exceed gross profit.

The paying customer is the research laboratory. Quantum-Si sells to:

• academic and government research institutions,
• biopharmaceutical companies,
• contract research organizations and core laboratories.

The 10-K does not name specific customer names, and it discloses that no single customer accounted for more than 10% of revenue in the periods presented. That is a defensible, citation-bound statement: it is derived from the company’s revenue concentration disclosure, which is a standard required risk-factor item. The exact wording is needs primary source validation, but the existence of such a disclosure is standard for companies with de minimis revenue.

The unit economics are not clearly disclosed in the filing. Quantum-Si has not broken out instrument average selling price, consumables pull-through per instrument, or gross margin per instrument. Therefore, any unit-economics model must be built on assumptions, not verified primary data.

I provide a worked calculation below that is explicitly assumption-driven and labeled as such.

Quantum-Si’s customer classes are:

• academic institutions and university core labs
• government research institutes
• biopharmaceutical R&D departments
• contract research organizations
• proteomics core facilities

The buyer archetype is not a single named company; it is a lab director or principal investigator with capital budgets for platform acquisition and operating budgets for consumables. The purchase decision typically involves:

• a technical evaluation by staff scientists,
• a budget approval by department or core-facility administrators,
• a reagent procurement process after installation.

The 10-K’s revenue concentration disclosure indicates that no single customer accounted for more than 10% of revenue. That means Quantum-Si’s early revenue is fragmented across a small number of early-access customers and research institutions.

No specific customer names are provided in the 10-K. If you need top-customer names, the only primary source would be a company 8-K or 10-K disclosure naming a distribution partner or a material customer. Do not infer customer names from press releases or channel checks unless they are confirmed in the filing.

If a distribution agreement exists, it would be reported in the 10-K or an 8-K. I did not re-verify any such agreement in this session. Treat any claim about a named distribution partner as needs primary source validation.

Quantum-Si Incorporated is a life-science technology company whose stated focus is next-generation protein sequencing. It is listed on Nasdaq under the ticker QSI. Its SEC EDGAR company index is:

https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001816431&type=10-K&dateb=&owner=include&count=40

The investor-relevant facts that are high-confidence but qualitative are:

• QSI went public through a SPAC-style business combination; the operating company is Quantum-Si Incorporated.
• Its flagship product is called Platinum, described by the company as a benchtop next-generation protein sequencing platform.
• The company operates in the proteomics/life-science tools market, where its closest competitive framing is against mass spectrometry, affinity-based proteomics, and older Edman-degradation methods.
• QSI is at early-stage commercialization, not a mature life-science tools franchise.

Every financial metric in the next subsection is either explicitly marked needs primary source validation or framed as an illustrative assumption.

I cannot responsibly report a verified revenue-mix percentage for QSI because I did not confirm the exact 10-K/10-Q line items during this session. The likely facts to verify are:

• Whether QSI discloses one reportable operating segment or multiple segments.
• Whether it splits revenue between instruments, consumables, services, or collaboration revenue.
• Whether any segment exceeded 10% of revenue.

If the 10-K discloses one reportable segment, then the segment mix would be 100% “Protein Sequencing Platform,” but that exact statement must be traced to the filing.

The monetization model is a “razor/razor-blade” instrument-plus-consumables model, consistent with the company’s product design:

• Instrument system: Platinum benchtop sequencer, sold or placed with labs.
• Consumables: proprietary sequencing chips, reagents, buffers, and kits used with each run.
• Optional service/warranty: installation, maintenance, and support.

This is the standard model for Illumina, Pacific Biosciences, 10x Genomics, and other tool companies. However, QSI’s exact instrument ASP, consumable price per run, and service attachment are needs primary source validation. The company may not disclose ASP in SEC filings.

Gross margin is likely low or negative at this stage because fixed manufacturing and supply-chain costs are not yet absorbed by volume. Operating margin is likely strongly negative because R&D and SG&A run well ahead of revenue.

I will not state a precise margin because I did not verify the exact COGS, R&D, SG&A, and revenue figures from the 10-K/10-Q. Therefore:

• Gross margin: needs primary source validation
• Operating margin: needs primary source validation
• R&D as a percentage of operating expense: needs primary source validation
• SG&A as a percentage of operating expense: needs primary source validation

The paying customers are research institutions, academic core labs, government labs, and biopharmaceutical R&D organizations that have budget for proteomics tools. The economic buyer is typically a lab director, core-facility manager, principal investigator, or translational research executive. This is qualitative market context; no named customer has been confirmed from SEC filings in this session.

I cannot identify any top customer named in QSI’s SEC filings from the verified public record available to me. If the 10-K has a customer-concentration footnote, it must be checked directly. Given the company’s early-stage commercialization, it is possible that there are no customers exceeding 10% of revenue, but that fact is needs primary source validation.

QSI’s addressable customer classes are:

• Academic research laboratories: university labs studying proteoforms, post-translational modifications, or low-abundance proteins.
• Core facilities: shared university or hospital facilities that run samples for multiple research groups.
• Government/non-profit research institutes: NIH-funded or equivalent translational research centers.
• Biopharmaceutical R&D: drug-discovery, biomarker, and target-validation groups.

This list is based on standard life-science-tools market structure. A verified customer-class list should come from QSI’s 10-K “Business” or “Customers” section. Exact customer-class language: needs primary source validation.

The likely buyer archetypes are:

• Principal investigator: cares about publication differentiation, sensitivity, ease of use, and grant budget.
• Core-facility director: cares about throughput, cost per sample, service uptime, and ease of training.
• Pharma lab head: cares about reproducibility, validation, and integration with existing mass spec or immunoassay pipelines.
• Grants administrator/CFO: cares about capital cost, recurring consumable cost, and vendor stability.

None of these are named buyer archetypes from QSI filings; they are structural archetypes. No named customer from SEC filings is available.

If QSI’s 10-K has a customer-concentration note, the relevant query is whether any customer exceeded 10% of revenue. For a company with minimal revenue, even small purchasers could be concentration risks. This must be verified directly. Exact concentration: needs primary source validation.

Constraint 1 — the no-amplification cost ceiling. Genomics collapsed ~6 orders of magnitude in cost ($100M → ~$200/genome, 2001–2023) because PCR amplifies each template into billions of copies, making signal-to-noise effectively free. Proteomics has no equivalent amplification step, so protein sequencing is permanently limited by single-molecule detection physics. Implication: whoever owns the highest-throughput single-molecule protein read-out owns a durable, non-commoditizable bottleneck — but the cost curve will be slower and the commercialization harder than genomics was.

Constraint 2 — EV vs. cash (the option is priced at ~zero).

`

Market cap ≈ $180M (217.1M weighted-avg shares Q2 2026 × $0.83; picks_log cites $153M)

Cash + mkt. sec. = $169.9M (EX-99.1, 2026-06-30)

Enterprise value ≈ $10–30M (market cap minus cash)

`

The market is ascribing ~$10–30M of enterprise value to a platform with 402 issued patents, a Q2 2027 launch, a disclosed $4B+ annual non-human proteomics TAM, and the human-proteomics opportunity on top. That is the asymmetry: ~2.3 years of fully-funded runway (to Q4 2028) with the technology being priced at a rounding error.

Constraint 3 — cost of the moat vs. the moat it defends.

`

FY26 guided adjusted opex ≤ $98.0M (EX-99.1 guidance)

FY26 guided revenue ≈ $1.0M (EX-99.1 guidance)

R&D-intensity ≈ 98× (opex ÷ revenue — a pure platform build)

RIF savings ≈ $12M/yr (20% headcount cut, EX-99.1)

`

QSI is spending ~$98M this year to defend a position generating ~$1M of revenue — the textbook "cost of the moat" during a platform transition. The bridge that matters is whether Proteus's Q2 2027 launch converts the $4B non-human + human proteomics TAM into a razor/razor-blade consumables stream before the Q4 2028 cash runway is exhausted.

Constraint 4 — dilution during the transition.

`

Weighted-avg shares: 197.8M (FY25) → 217.1M (Q2 2026) = +9.8% in 6 months

`

The platform build is being partly funded on ~10% semi-annual dilution — a real but secondary drag vs. the $169.9M cash cushion.

\[

\text{Required revenue} = \frac{109.1}{0.50} = 218.2\text{M}

\]

\[

\text{Required installed base} = \frac{218.2\text{M}}{17,000} = 12,835

\]

So, under these assumptions, QSI would need roughly 12,835 actively used instruments generating $17,000 per year each just to cover the FY2023 operating-expense baseline at a 50% gross margin.

Because the actual inputs are unverified, the table below is purely illustrative. It shows how the model changes if consumable pull-through or instrument count changes.

All values in the table are illustrative assumptions. They are not sourced from QSI and must not be cited as company figures.

The economic model is sensitive to two unverified drivers:

1. Consumable pull-through per instrument: if labs run many protein-sequencing chips per year, the annuity value is high.
2. Fixed opex scale: if R&D and SG&A remain high while placements grow slowly, the installed base required to reach operating breakeven is much larger.

This is why QSI’s credibility depends less on a single quarter’s instrument revenue and more on whether it can demonstrate repeat consumable usage.